Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome폐렴구균 관련 용혈성 요독 증후군이 있는 아동에서의 보체 활성화Brief Report Published on 2021-02-042024-07-30 Journal: Pediatric Nephrology (Berlin, Germany) [Category] 폐렴구균 감염증, [키워드] children complement eculizumab hemolytic uremic syndrome Streptococcus pneumonia [DOI] 10.1007/s00467-021-04952-w PMC 바로가기 [Article Type] Brief Report
Complement Inhibition in Severe COVID-19 Acute Respiratory Distress SyndromePediatrics Published on 2020-12-292022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] Acute kidney injury acute lung injury acute respiratory distress acute respiratory distress syndrome (ARDS) AKI animal model ARDS Asymptomatic children children with COVID-19 complement convalescent plasma COVID - 19 COVID-19 Critically ill Deterioration died disease eculizumab Immune-mediated inflammatory pathways inhibition lung Lung function lung tissue mild illness MOST patients with COVID-19 pediatric respiratory SARS-CoV SARS-CoV-2 supported syndrome treated with COVID-19 [DOI] 10.3389/fped.2020.616731 PMC 바로가기 [Article Type] Pediatrics
Eculizumab treatment for renal failure in a pediatric patient with COVID-19COVID-19 소아 환자의 신부전을 위한 Eculizumab 치료Case Reports Published on 2020-12-012022-09-12 Journal: Journal of Nephrology [Category] MERS, SARS, 진단, [키워드] Acute kidney injury appear children complement dysregulation complex Complication COVID-19 eculizumab Hospitalized information kidney multifactorial patient with COVID-19 pediatric renal thrombotic treated Treatment while with COVID-19 [DOI] 10.1007/s40620-020-00858-2 PMC 바로가기 [Article Type] Case Reports
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept studyResearch article Published on 2020-11-052022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 치료법, [키워드] acute respiratory distress syndrome acute respiratory illness approach arterial oxygen tension Bacteremia benefit Biomarker Biomarkers Blood urea nitrogen C5 inhibitor caused changes in clinical laboratory complement Complement pathway conjugated bilirubin coronavirus COVID-19 Cytokines decrease eculizumab Efficacy and safety finding fraction funding Hemolysis hemorrhage hypoxia IMPROVE Inflammation inhibitor intensive care Laboratory Lactate log-rank test nonrandomized oxygen pathway Patient patients treated Platelet Pneumonia Primary outcome Prothrombin time rapid increase reduce reduced SARS-COV-2 infection Sepsis Serious Adverse Event severe COVID-19 significantly more standard care survival treated Treatment Ventilator-associated pneumonia viral infection [DOI] 10.1016/j.eclinm.2020.100590 [Article Type] Research article
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacyResearch article Published on 2020-11-012022-10-05 Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, 바이오마커, [키워드] abrogate Activation acute respiratory distress AMY-101 anti-inflammatory response ARDS Biomarkers blockade C-reactive protein C3 inhibition C3a C5 blockade C5a candidate drug clinical evidence Clinical finding Cohort complement consequence COVID-19 COVID-19 hyper-inflammation COVID-19 patient COVID-19 therapeutics detrimental drug candidate Drug efficacy eculizumab effector Efficacy elicit exploratory study faster hyper-inflammation IL-6 levels immunopathology immunothrombosis implicated independent indicate inhibitor inhibitory Intervention LDH Lung function lymphocyte monoclonal antibody multi-organ failure NET neutrophil counts Neutrophil extracellular trap offer outcome pathogenic pathway reflected robust SARS-COV-2 infection SC5b-9 serum severe COVID-19 patients Support syndrome therapeutic Thromboinflammation thrombotic trials upstream [DOI] 10.1016/j.clim.2020.108598 [Article Type] Research article
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19Case Reports Published on 2020-10-012023-07-11 Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, [키워드] complement coronavirus COVID-19 eculizumab lectin pathway MASP2. [DOI] 10.1016/j.clim.2020.108555 PMC 바로가기 [Article Type] Case Reports
New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndromearticle Published on 2020-09-302024-09-01 Journal: Pediatric Nephrology (Berlin, Germany) [Category] 폐렴구균 감염증, [키워드] Alternative complement pathway eculizumab P-HUS Plasmapheresis [Article Type] article
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talkingReview article Published on 2020-09-012022-10-05 Journal: Virus research [Category] SARS, 비임상, 치료제, [키워드] amplification Anakinra Baricitinib clinical trial Coagulation Coagulopathy coronavirus Corticosteroid COVID-19 Cytokine storm Dexamethasone drug drugs eculizumab emapalumab heparin Human implicated include Infection Inflammation inflammatory phase Lopinavir/ritonavir mild infection Remdesivir response responsible review ruxolitinib SARS-CoV-1 SARS-CoV-2 Severe case severe cases suggested therapeutic option Therapies therapy Tocilizumab Treatment [DOI] 10.1016/j.virusres.2020.198070 [Article Type] Review article
nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational TherapeuticsCell and Developmental Biology Published on 2020-07-102022-10-31 Journal: Frontiers in Cell and Developmental Biology [Category] COVID-19, [키워드] acute respiratory syndrome Affect analyzed antiviral activity antiviral drug Clinical efficacy Combination coronavirus Corticosteroids COVID-19 eculizumab Efficacy environmental factor Epidemic evaluate exhibited Favipiravir genetic diversity Good Hydroxychloroquine immunomodulators inhibitor molecular monoclonal nCOVID-19 novel coronavirus disease Pathogenesis Patient patients polyclonal antibody Potential RdRP RdRp inhibitors Remdesivir RNA-dependent RNA polymerase SARS-CoV-2 temperature therapeutic option Therapeutics Transmission treat umifenovir virus widespread worldwide pandemic Wuhan, China [DOI] 10.3389/fcell.2020.00616 PMC 바로가기 [Article Type] Cell and Developmental Biology
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cureReview Article Published on 2020-06-242023-06-16 Journal: Annals of Hematology [Category] MERS, SARS, [키워드] complement COVID-19 eculizumab Endothelium HIF-1-alpha Imatinib SARS-CoV thrombosis [DOI] 10.1007/s00277-020-04138-8 PMC 바로가기 [Article Type] Review Article